Focused On-demand Library for SH3 domain-binding glutamic acid-rich-like protein 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9UJC5

UPID:

SH3L2_HUMAN

Alternative names:

Fovea-associated SH3 domain-binding protein

Alternative UPACC:

Q9UJC5; A8MQU2; Q2VPC2; Q5VV96; Q6NSK8; Q6P9E8; Q7Z734; Q8IWD3; Q9BPY5

Background:

The SH3 domain-binding glutamic acid-rich-like protein 2, also known as Fovea-associated SH3 domain-binding protein, plays a crucial role in cellular processes. Its unique structure, characterized by the SH3 domain, suggests a specific interaction with other proteins, facilitating various cellular functions.

Therapeutic significance:

Understanding the role of SH3 domain-binding glutamic acid-rich-like protein 2 could open doors to potential therapeutic strategies. Its involvement in critical cellular processes makes it a promising target for drug discovery, aiming to modulate its activity for therapeutic benefits.